MiNK Therapeutics, Inc. Research and Development Expense
MiNK Therapeutics, Inc. (INKT) reported Research and Development Expense of $1.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- MiNK Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.89M, a 2.61% increase year-over-year.
- MiNK Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $1.20M, a 4.58% decline year-over-year.
- MiNK Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $1.51M, a 7.62% increase year-over-year.
- MiNK Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $1.14M, a 111.45% increase year-over-year.
- MiNK Therapeutics, Inc. research and development expense for fiscal 2025 was $5.76M, a 9.13% decline from fiscal 2024.
- MiNK Therapeutics, Inc. research and development expense for fiscal 2024 was $6.34M, a 59.10% decline from fiscal 2023.
- MiNK Therapeutics, Inc. research and development expense for fiscal 2023 was $15.49M, a 32.99% decline from fiscal 2022.
- MiNK Therapeutics, Inc. research and development expense for fiscal 2022 was $23.12M, a 65.51% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.89M 10-Q · filed 2026-08-13 | $3.09M 10-Q · filed 2026-08-13 | $4.60M derived: sum of 3 quarters · filed 2026-08-13 | $5.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-15 | $2.72M derived: sum of 2 quarters · filed 2026-05-15 | $3.86M derived: sum of 3 quarters · filed 2026-05-15 | $5.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.66M derived: sum of 2 quarters · filed 2026-03-31 | $4.50M derived: sum of 3 quarters · filed 2026-08-13 | $5.76M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.14M 10-Q · filed 2025-11-14 | $2.98M derived: sum of 2 quarters · filed 2026-08-13 | $4.24M 10-Q · filed 2025-11-14 | $5.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.84M 10-Q · filed 2026-08-13 | $3.10M 10-Q · filed 2026-08-13 | $4.51M derived: sum of 3 quarters · filed 2026-08-13 | $5.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-15 | $2.67M derived: sum of 2 quarters · filed 2026-05-15 | $3.21M derived: sum of 3 quarters · filed 2026-05-15 | $5.05M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.95M derived: sum of 2 quarters · filed 2026-03-31 | $3.79M derived: sum of 3 quarters · filed 2026-03-31 | $6.34M 10-K · filed 2026-03-31 |
| 2024-09-30 | $540.64K 10-Q · filed 2025-11-14 | $2.38M derived: sum of 2 quarters · filed 2025-11-14 | $4.93M 10-Q · filed 2025-11-14 | $8.24M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.84M 10-Q · filed 2025-08-14 | $4.39M 10-Q · filed 2025-08-14 | $7.70M derived: sum of 3 quarters · filed 2025-08-14 | $11.13M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.55M 10-Q · filed 2025-05-15 | $5.86M derived: sum of 2 quarters · filed 2025-05-15 | $9.29M derived: sum of 3 quarters · filed 2025-05-15 | $13.85M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $6.74M derived: sum of 2 quarters · filed 2025-03-18 | $11.30M derived: sum of 3 quarters · filed 2025-03-18 | $15.49M 10-K · filed 2025-03-18 |
| 2023-09-30 | $3.43M 10-Q · filed 2024-11-14 | $7.99M derived: sum of 2 quarters · filed 2024-11-14 | $12.18M 10-Q · filed 2024-11-14 | $17.99M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $4.56M 10-Q · filed 2024-08-13 | $8.75M 10-Q · filed 2024-08-13 | $14.56M derived: sum of 3 quarters · filed 2024-08-13 | $20.71M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.19M 10-Q · filed 2024-05-14 | $10.01M derived: sum of 2 quarters · filed 2024-05-14 | $16.16M derived: sum of 3 quarters · filed 2024-05-14 | $22.03M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $11.96M derived: sum of 2 quarters · filed 2024-03-21 | $17.84M derived: sum of 3 quarters · filed 2024-03-21 | $23.12M 10-K · filed 2024-03-21 |
| 2022-09-30 | $6.15M 10-Q · filed 2023-11-14 | $12.03M derived: sum of 2 quarters · filed 2023-11-14 | $17.30M 10-Q · filed 2023-11-14 | $21.25M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.88M 10-Q · filed 2023-08-10 | $11.15M 10-Q · filed 2023-08-10 | $15.10M derived: sum of 3 quarters · filed 2023-08-10 | $18.44M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.28M 10-Q · filed 2023-05-11 | $9.23M derived: sum of 2 quarters · filed 2023-05-11 | $12.56M derived: sum of 3 quarters · filed 2023-05-11 | $16.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $7.28M derived: sum of 2 quarters · filed 2023-03-24 | $10.87M derived: sum of 3 quarters · filed 2023-03-24 | $13.97M 10-K · filed 2023-03-24 |
| 2021-09-30 | $3.33M 10-Q · filed 2022-11-03 | $6.92M derived: sum of 2 quarters · filed 2022-11-03 | $10.02M 10-Q · filed 2022-11-03 | $10.80M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $3.58M 10-Q · filed 2022-08-15 | $6.68M 10-Q · filed 2022-08-15 | $7.47M derived: sum of 3 quarters · filed 2022-08-15 | $9.97M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $3.10M 10-Q · filed 2022-05-13 | $3.89M derived: sum of 2 quarters · filed 2022-05-13 | $6.39M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $787.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $3.29M derived: sum of 2 quarters · filed 2022-03-18 | $9.51M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $2.50M 10-Q · filed 2021-11-29 | $8.72M 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |